Mural Oncology Paints Itself Into A Corner After Nemvaleukin Alfa Fails

In November 2023, Alkermes plc (ALKS) spun off its oncology division into a new company: Mural Oncology plc (MURA). Armed with $275 million in cash, no debt, and a clean slate, the company was designed as a single-focus biotech aimed at bringing nemvaleukin alfa, an engineered IL-2 cytokine, through late-stage development.

Less than two years later, the experiment is over. Mural Oncology has halted all trials, laid off most of its staff, and initiated a strategic review. The company expects to have under $50 million in cash remaining by the end of 2025—suggesting a liquidating distribution of less than $2 per share.

🧪 Caroline Loew at the Helm

Caroline Loew, Ph.D., an industry veteran with prior leadership roles at Glympse Bio and Bristol Myers Squibb, was appointed CEO at the time of the spin. She was tasked with guiding the company’s sole candidate—nemvaleukin alfa—through pivotal trials and toward commercialization.

🚨 ARTISTRY-7 & ARTISTRY-6: Clinical Failures

ARTISTRY-7 (Ovarian Cancer)

On March 25, 2025, Mural announced that ARTISTRY-7, a Phase 3 trial combining nemvaleukin alfa with pembrolizumab in platinum-resistant ovarian cancer, failed to improve overall survival. The hazard ratio hovered near 1.0, with median survival essentially identical to the control arm.

ARTISTRY-6 (Melanoma)

Shortly afterward, ARTISTRY-6—a Phase 2 study in mucosal melanoma—also failed to meet internal benchmarks for efficacy. The company discontinued all development of nemvaleukin alfa and began wind-down procedures.

⚠️ Warning Signs Were Clear

Mural’s downfall was disappointing—but not surprising. The warning signs were evident at the time of the spin-off:

1. Peer Failures in IL-2 Therapies

By 2023, the field of engineered IL-2 cytokines had already been rocked by failure. Most notably, Nektar Therapeutics’ bempegaldesleukin, once considered a next-gen immunotherapy, failed multiple Phase 3 trials—despite a high-profile partnership with Bristol Myers Squibb.

Nemvaleukin alfa was mechanistically distinct, but the writing was on the wall: IL-2 analogs were proving difficult to commercialize. Yet Mural pressed ahead with two ambitious trials.

2. Aggressive Cash Burn Despite Large War Chest

Mural started with $275 million in cash, yet projected that would last only about two years. That implied a burn rate of $130–140 million per year—staggering for a company with:

• A single licensed asset
• No commercial products
• No backup pipeline

The risk: if nemvaleukin failed, the company would have nothing left. That’s exactly what happened.

💸 From $275M to <$50M in Under 2 Years

As of June 30, 2025, Mural reported $77.1 million in cash remaining. Wind-down costs and restructuring charges are expected to consume another $30+ million. That leaves less than $2/share for shareholders who held post-spin.

📉 What About Alkermes?

Alkermes shareholders fared better. Since the spin:

• ALKS shares rose from ~$26 to ~$30, a ~15% gain
• The company refocused on its core neuroscience business
• Operational clarity improved, and investor confidence returned

While not a massive rally, it was a positive outcome compared to the 80%+ loss MURA investors now face.

🧾 Mural Oncology Reaches The End Of The Line

Mural Oncology was structurally clean, well-funded, and focused. But it was also vulnerable. Nemvaleukin alfa, once positioned as the future of IL-2 therapy, failed to deliver. Without a pipeline, fallback strategy, or partnerships, Mural had no path forward.

Shareholders are now left holding a rapidly evaporating pile of cash. Liquidation is the likely endgame—leaving a cautionary tale in its wake.

We’ll continue to monitor developments and post updates when a shareholder record date is announced or if a surprise acquisition emerges.

Disclosure: The author holds no position in any stock mentioned